Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Australia Finds ‘Unacceptable’ Levels Of NDMA In 80% of Ranitidine Batches

Oct 30 2019

• By Tom Gallen

Drugs question mark

Related Content

EMA Tells Firms To Evaluate OTCs For Carcinogenic Nitrosamines

Sep 27 2019

Testing Ranitidine With Too Much Heat Could Generate NDMA, FDA Says

Oct 02 2019

Additional Topics

Australia Asia Pacific Drug Safety Drug Review Manufacturing OTC Drugs Regulation Consumer

More from Asia

More from Geography

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window